GPR162 and Alzheimer disease: In comparing AD with HC in validation cohort, the AUC was 0.7176 for GABRD+-carrying pTau217 EVs, 0.5452 for GPR162+-carrying pTau217 EVs, 0.5272 for the distribution of GABRD+ carrying pTau217 EVs, and 0.5108 for the distribution of GPR162+ carrying pTau217 EVs.